HC Wainwright & Co. reaffirmed TuHURA Biosciences Inc (HURA) at Buy on November 17, 2026.
The past 90 days include one active firm, with one rating the stock bullish. The consensus price targets from seven analysts as of November 10, 2026, have a mean of $8.20, a median of $8.16 and a range of $6.26 to $10.50.
Consensus Q4 FY2026 EPS is -$0.14, with revenue at $0. The next earnings report is on March 29, 2027.
